Positive Q3 for Bayer Healthcare

The Bayer Group continues its positive business momentum according to its third quarter financial results. Sales were level year on year at €9643 million.

New pharmaceutical products contributed over €400 million to Bayer HealthCare’s sales, with its pharmaceuticals business reporting a 3.1% growth this quarter. This strong development was mainly driven by the anticoagulant Xarelto (Rivaroxaban), the eye medicine Eylea (aflibercept), and the cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride injection) .Xarelto became the global leader in the new oral anticoagulants.

“HealthCare registered encouraging growth, largely due to the outstanding sales performance for our new pharmaceutical products.”

Bayer Management Board Chairman Dr. Marijn Dekkers.

Bayer expects sales for the full year 2013 to increase by a currency- and portfolio-adjusted 4–5 % to approximately €40 billion.



Related news:

Bayer says new products push profits higher in Q3 (Medical Xpress)

Reference links:

Bayer press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.